Venaxis


UPDATE: Canaccord Downgrades Venaxis After Significant FDA Setback

In a research report sent to investors, Canaccord Genuity analyst Mark Massaro downgraded shares of Venaxis (NASDAQ:APPY) from Buy to Hold, and reduced the …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts